GlassScriptPhysician profile
Scott Pearlman
NPI 1528138708
$1,818.63
in general payments reported to CMS, 2019-2025
22 companies · $1,131 in 2025
The $1,131 reported for 2025 was more than what 96% of Emergency Medicine providers received nationally (typical 2025 total: $57.10).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $125 · 2024: $563 · 2025: $1,131.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,694.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,693.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $319.21 | 2024-2025 | |
| Qol Medical, LLC | $186.54 | 2024-2025 | Sucraid, Sucraid |
| Novo Nordisk INC | $156.86 | 2024-2025 | Ozempic, Rybelsus |
| Tolmar, INC. | $155.59 | 2024-2025 | Jatenzo |
| Viiv Healthcare Company | $144.34 | 2024-2025 | Dovato, Apretude |
| Amgen INC. | $136.91 | 2024-2025 | Repatha, Repatha, Otezla |
| Allergan, INC. | $125.00 | 2019 | |
| Lilly USA, LLC | $100.34 | 2024-2025 | Zepbound, Mounjaro |
| Pfizer INC. | $86.29 | 2025 | |
| Exact Sciences Corporation | $67.72 | 2025 | Cologuard Collection Kit |
| Emd Serono, INC. | $53.76 | 2025 | |
| Antares Pharma, INC. | $50.56 | 2025 | Xyosted |
| Abbvie INC. | $40.94 | 2024-2025 | |
| Theratechnologies INC. | $25.20 | 2025 | Egrifta, Trogarzo |
| Lucid Diagnostics INC. | $24.51 | 2025 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironwood Pharmaceuticals, INC | $22.98 | 2024 | |
| Merck Sharp & Dohme LLC | $22.33 | 2025 | Pifeltro |
| Heartflow, INC. | $21.91 | 2025 | |
| Glaxosmithkline, LLC. | $21.67 | 2024 | Trelegy Ellipta |
| Corcept Therapeutics | $20.38 | 2025 | Korlym |
| Janssen Biotech, INC. | $18.58 | 2025 | Tremfya |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $17.01 | 2024 | Xifaxan |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Pearlman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.